ATALANTA-1: Promising Data for Novel CAR T-Cell Therapy
The CD19-directed CAR T-cell therapy GLPG5101 was analyzed for safety and efficacy in patients with relapsed or refractory non-Hodgkin lymphoma.
Read MoreJan 3, 2025
The CD19-directed CAR T-cell therapy GLPG5101 was analyzed for safety and efficacy in patients with relapsed or refractory non-Hodgkin lymphoma.
Read MoreSep 13, 2024
THURSDAY, Sept. 12, 2024 (HealthDay News) — The overall second primary malignancy (SPM)...
Read MoreJul 31, 2024
TUESDAY, July 30, 2024 (HealthDay News) — New-onset cytokine release syndrome (CRS) and...
Read MoreApr 26, 2024
THURSDAY, April 25, 2024 (HealthDay News) — For patients with relapsed or refractory...
Read MoreApr 24, 2024
The following is a summary of “Human Herpesvirus-6 Reactivation and Disease Are Infrequent...
Read MoreMar 21, 2024
WEDNESDAY, March 20, 2024 (HealthDay News) — Second primary malignancies (SPMs) represent a...
Read MoreMar 19, 2024
MONDAY, March 18, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved...
Read MoreMar 3, 2024
Projected five-year incidence of 15.2 and 2.3% for solid and hematologic malignancies after CAR T-cell immunotherapy.
Read MoreFeb 22, 2024
WEDNESDAY, Feb. 21, 2024 (HealthDay News) — CD19 chimeric antigen receptor (CAR) T-cell...
Read MoreFeb 16, 2024
THURSDAY, Feb. 15, 2024 (HealthDay News) — For patients with diffuse large B-cell lymphoma...
Read MoreFeb 5, 2024
FRIDAY, Feb. 2, 2024 (HealthDay News) — The incidence of secondary primary malignancy after...
Read MoreJan 25, 2024
Citing recent indications that CAR T-cell therapy may cause rare secondary cancers, the U.S. Food...
Read MoreJan 22, 2024
The following is a summary of “Recent Bendamustine Treatment Before Apheresis Has a Negative...
Read MoreDec 13, 2023
TUESDAY, Dec. 12, 2023 (HealthDay News) — For patients with relapsed or refractory large...
Read MoreApr 17, 2023
The following is a summary of “CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in...
Read MoreApr 4, 2023
The following is a summary of “CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed...
Read MoreMar 28, 2023
The following is a summary of “CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed...
Read MoreFeb 27, 2023
Chimeric antigen receptor (CAR) T-cell therapy has improved the limited overall survival (OS) of...
Read MoreAug 17, 2022
After receiving CD19 chimeric antigen receptor T-cell therapy (CART19), patients with relapsed or...
Read MoreApr 20, 2022
CAR T-cell treatment can result in long-term remissions of relapsed/refractory B-acute...
Read MoreSed vitae nulla id ipsum molestie scelerisque vitae vitae ligula. Fusce a massa tortor.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.